Usefulness of dynamic regression time series models for studying the relationship between antimicrobial consumption and bacterial antimicrobial resistance in hospitals: a systematic review
Backgroung Antimicrobial resistance (AMR) is on the rise worldwide. Tools such as dynamic regression (DR) models can correlate antimicrobial consumption (AMC) with AMR and predict future trends to help implement antimicrobial stewardship programs (ASPs). Main body We carried out a systematic review of the literature up to 2023/05/31, searching in PubMed, ScienceDirect and Web of Science. We screened 641 articles and finally included 28 studies using a DR model to study the correlation between AMC and AMR at a hospital scale, published in English or French. Country, bacterial species, type of sampling, antimicrobials, study duration and correlations between AMC and AMR were collected. The use of β-lactams was correlated with cephalosporin resistance, especially in Pseudomonas aeruginosa and Enterobacterales. Carbapenem consumption was correlated with carbapenem resistance, particularly in Pseudomonas aeruginosa, Klebsiella pneumoniae and Acinetobacter baumannii. Fluoroquinolone use was correlated with fluoroquinolone resistance in Gram-negative bacilli and methicillin resistance in Staphylococcus aureus. Multivariate DR models highlited that AMC explained from 19 to 96% of AMR variation, with a lag time between AMC and AMR variation of 2 to 4 months. Few studies have investigated the predictive capacity of DR models, which appear to be limited. Conclusion Despite their statistical robustness, DR models are not widely used. They confirmed the important role of fluoroquinolones, cephalosporins and carbapenems in the emergence of AMR. However, further studies are needed to assess their predictive capacity and usefulness for ASPs..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Antimicrobial resistance and infection control - 12(2023), 1 vom: 12. Sept. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Laffont-Lozes, Paul [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| BKL: | |
|---|---|
| Themen: |
Antimicrobial |
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1186/s13756-023-01302-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR053048180 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR053048180 | ||
| 003 | DE-627 | ||
| 005 | 20240323064759.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230912s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13756-023-01302-3 |2 doi | |
| 035 | |a (DE-627)SPR053048180 | ||
| 035 | |a (SPR)s13756-023-01302-3-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 15,3 |2 ssgn | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 084 | |a 44.38 |2 bkl | ||
| 084 | |a 44.75 |2 bkl | ||
| 100 | 1 | |a Laffont-Lozes, Paul |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Usefulness of dynamic regression time series models for studying the relationship between antimicrobial consumption and bacterial antimicrobial resistance in hospitals: a systematic review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Backgroung Antimicrobial resistance (AMR) is on the rise worldwide. Tools such as dynamic regression (DR) models can correlate antimicrobial consumption (AMC) with AMR and predict future trends to help implement antimicrobial stewardship programs (ASPs). Main body We carried out a systematic review of the literature up to 2023/05/31, searching in PubMed, ScienceDirect and Web of Science. We screened 641 articles and finally included 28 studies using a DR model to study the correlation between AMC and AMR at a hospital scale, published in English or French. Country, bacterial species, type of sampling, antimicrobials, study duration and correlations between AMC and AMR were collected. The use of β-lactams was correlated with cephalosporin resistance, especially in Pseudomonas aeruginosa and Enterobacterales. Carbapenem consumption was correlated with carbapenem resistance, particularly in Pseudomonas aeruginosa, Klebsiella pneumoniae and Acinetobacter baumannii. Fluoroquinolone use was correlated with fluoroquinolone resistance in Gram-negative bacilli and methicillin resistance in Staphylococcus aureus. Multivariate DR models highlited that AMC explained from 19 to 96% of AMR variation, with a lag time between AMC and AMR variation of 2 to 4 months. Few studies have investigated the predictive capacity of DR models, which appear to be limited. Conclusion Despite their statistical robustness, DR models are not widely used. They confirmed the important role of fluoroquinolones, cephalosporins and carbapenems in the emergence of AMR. However, further studies are needed to assess their predictive capacity and usefulness for ASPs. | ||
| 650 | 4 | |a Antimicrobial |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Dynamic regression |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Healthcare-associated infections |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Resistance |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Time series analysis |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Larcher, Romaric |4 aut | |
| 700 | 1 | |a Salipante, Florian |4 aut | |
| 700 | 1 | |a Leguelinel-Blache, Geraldine |4 aut | |
| 700 | 1 | |a Dunyach-Remy, Catherine |4 aut | |
| 700 | 1 | |a Lavigne, Jean-Philippe |4 aut | |
| 700 | 1 | |a Sotto, Albert |4 aut | |
| 700 | 1 | |a Loubet, Paul |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Antimicrobial resistance and infection control |d BioMed Central, 2012 |g 12(2023), 1 vom: 12. Sept. |w (DE-627)SPR032269641 |w (DE-600)2666706-X |x 2047-2994 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:1 |g day:12 |g month:09 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s13756-023-01302-3 |z kostenfrei |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 936 | b | k | |a 44.38 |q VZ |
| 936 | b | k | |a 44.75 |q VZ |
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 1 |b 12 |c 09 | ||